Sonata Therapeutics
Arindam Mondal, Ph.D., currently serves as Scientist II in In Vivo Pharmacology at Sonata Therapeutics since November 2022. Prior experience includes roles as Postdoctoral Research Associate and Postdoctoral Fellow at Rutgers University–New Brunswick from September 2018 to November 2022, and as a Visiting Research Scientist and Postdoctoral Research Associate at Florida A&M University from August 2016 to September 2018. Additional positions include Post-doctoral Researcher at Union University and Graduate Research Fellow at Beckman Laser Institute Korea. Arindam Mondal's research expertise encompasses cancer cell biology, natural compounds, photodynamic therapy, molecular biology, and stem cell biology. Educational qualifications include a Ph.D. in Cancer Biology from Dankook University and multiple degrees from the University of Kalyani, culminating in a Bachelor of Science in Chemistry.
Sonata Therapeutics
Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.